Higher psoriasis drug doses show promise in small trial
NCT ID NCT05283135
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This pilot study tested higher-than-standard doses of risankizumab in 20 adults with moderate-to-severe plaque psoriasis. The goal was to see if higher doses could better clear the skin and reduce certain immune cells (resident memory T cells) that may cause psoriasis to return. Results suggest higher doses may improve long-term skin clearance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Medical Research Center
Portland, Oregon, 97201, United States
Conditions
Explore the condition pages connected to this study.